ImmuPharma plc

Equities

IMM

GB0033711010

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 08:10:43 2024-05-20 am EDT			5-day change	1st Jan Change
2.22 ^GBX	-7.69%		+3.26%	+33.17%

Apr. 29	Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	CI
Apr. 02	Immupharma jumps amid new IP strategy for P140 technology platform	AN

ImmuPharma annual loss narrows as R&D spending reduced

May 11, 2023 at 06:50 am EDT

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Current stock price: 2.70 pence each, down 6.4% on Thursday in London

12-month change: down 55%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about ImmuPharma plc

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	Apr. 29	CI
Immupharma jumps amid new IP strategy for P140 technology platform	Apr. 02	AN
ImmuPharma plc Initiates New Intellectual Property Strategy to Significantly Enhance the Patent Life and Commercial Value for Its P140 Technology Platform	Apr. 02	CI
Incanthera says first order from skincare deal doubles	Mar. 25	AN
Stocks make tepid start to new week	Mar. 25	AN
AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss	Mar. 25	AN
EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up	Mar. 06	AN
EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows	Dec. 19	AN
Immupharma Decides to Move Directly to Late-stage Trial of Lupus Therapy	Dec. 19	MT
ImmuPharma Appoints Contract Research Organization for Late-stage Lupuzor Trial	Dec. 19	MT
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm	Dec. 19	CI
Incanthera signs skincare stocking deal, raises GBP1 million	Dec. 18	AN
ImmuPharma plc Announces Executive Appointments	Nov. 09	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	Nov. 07	CI
RA International loss narrows as revenue grows	23-09-07	AN
British Biopharmaceutical Company ImmuPharma Closes Retail Offer of New Shares	23-09-07	MT
FTSE 100 Ends Negative Month on Subdued Note	23-08-31	DJ
ImmuPharma Targets GBP2 Million Equity Raise; Stock Sinks 12%	23-08-31	MT
ImmuPharma launches GBP2 million fund raise as interim loss narrows	23-08-31	AN
Earnings Flash (IMM.L) IMMUPHARMA Reports H1 Revenue GBP69,959	23-08-31	MT
Earnings Flash (IMM.L) IMMUPHARMA Posts H1 Loss GBX-0.25	23-08-31	MT
ImmuPharma plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
ImmuPharma agrees 12 month extension to Incanthera warrant instrument	23-08-21	AN
ImmuPharma Secures 12-month Extension to Incanthera Warrant Instrument	23-08-21	MT
ImmuPharma Initiates Talks with Potential Partners for Licensing Deals	23-08-11	MT

Chart ImmuPharma plc

Duration

Period

More charts

Company Profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUPHARMA PLC	+33.17%	12.73M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research